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Abstract
Background: The successful implementation of maternal vaccination relies on results of clinical trials, considering
the prenatal and postnatal attendance at selected healthcare institutions. This study evaluated factors influencing
maternal/infant access to healthcare facilities to identify potential barriers to participation in future clinical trials on
maternal vaccination.
Methods: In this prospective, multi-centre, observational study, pregnant women (N = 3243) were enrolled at ten
sites across Panama, the Dominican Republic, South Africa, and Mozambique between 2012 and 2014. They
completed questionnaires at enrolment, delivery, and infant follow-up (90 days post-partum) visits, including
questions on transportation, phone accessibility, alternative childcare, gestational age at enrolment, delivery
location, and health status of their infant. Logistic regression was used to identify factors significantly associated
with return to study site for delivery or infant follow-up visits.
Results: Among 3229 enrolled women with delivery information, 63.6% (range across sites: 25.3–91.5%) returned to
study site for delivery. Older women and those at later gestational age at enrolment were more likely to deliver at the
study site. While heterogeneities were observed at site level, shorter travel time at delivery and increased transportation
costs at enrolment were associated with increased likelihood of women returning to study site for delivery. Among
3145 women with live-born infants, 3077 (95.3%) provided 90-day follow-up information; of these, 68.9% (range across
sites: 25.6–98.9%) returned to study site for follow-up visits. Women with other children and with lower transportation
costs at delivery were more likely to return to study site for follow-up visits. Among 666 infants reported sick, 94.3%
were taken to a healthcare facility, with only 41.9% (range across sites: 4.9–77.3%) to the study site.
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Conclusion: Although high retention was observed from enrolment through 90 days after delivery, post-partum
surveillance should be broadened beyond the study sites and additional follow-up visits should be planned
within the neonatal period. The factors influencing maternal/infant access to healthcare facilities and the issues
identified in this study should be taken into consideration in planning future clinical studies on maternal immunisation
in low- and middle-income countries.
Trial registration: The study was registered at ClinicalTrial.gov (NCT01734434) on November 22, 2012.
Keywords: Developing countries, Group B Streptococcus, Healthcare system, Immunisation, Infants, Pregnant women
Background
Between 1990 and 2015, the global under-five annual
mortality rate has declined by 53%, from 91 to 43 deaths
per 1000 live births [1]. Moreover, an acceleration in the
improvement of child survival has been observed during
this period, with annual rates of reduction in mortality
increasing from 1.8% in 1990–2000 to 3.9% in 2000–
2015 [1]. The decline in mortality has been slower in
neonates than in post-neonatal under-five children (47%
versus 58% globally), with neonatal mortality rates that
fell from 36 to 19 deaths per 1000 live births between
1990 and 2015. Almost 45% of the 5.9 million deaths
reported worldwide among children younger than 5 years
in 2015 occurred in neonates, and the neonatal period
remains the most vulnerable time for a child’s survival
[1–4]. The vast majority of newborn deaths and almost all
maternal deaths (99%) take place in developing countries
[3, 5]. As lack of access to quality healthcare at critical time
points prior to, during, and after delivery may influence
mortality rates [4, 5], identifying barriers to healthcare
utilisation could reduce infant and maternal deaths.
Immunisation of pregnant women can protect neonates
from diseases which may present within the first days of
life: tetanus vaccination is recommended by the World
Health Organisation [6], some countries have introduced
routine seasonal influenza vaccination [7], and others rec-
ommend primary or booster vaccination against pertussis
[8, 9]. Maternal vaccination against other diseases, such as
Group B Streptococcus (GBS), which can kill infants in the
first hours of life, is currently under investigation [10, 11].
GBS is a major cause of neonatal sepsis and meningitis,
and is classified as early-onset disease when presenting
between 0 to 6 days of age and late-onset disease when
presenting between 7 to 89 days of age [12]. In previous
clinical trials, a single dose of an investigational GBS
vaccine was administered to women at 24–35 weeks of
gestation, but the optimal vaccination schedule has not
been determined [10, 11].
The successful implementation of maternal vaccination
will rely on results of clinical trials, taking into account
the prenatal and postnatal attendance at the selected
healthcare institutions serving as study sites. This study
identified factors influencing whether pregnant women
would enrol in clinical trials and return to study site for
delivery, infant follow-up visits, or medical assistance in
case of infant disease. The aim was to identify potential
barriers to participation in future large-scale efficacy
trials of investigational GBS vaccines administered during
pregnancy.
Methods
This prospective, multi-centre, observational study was
conducted between November 2012 and January 2015 in
potential sites for a phase 3 maternal immunisation clinical
efficacy study in which pregnant women from countries
with reported high incidence of GBS disease in infants
could be enrolled. Although 13 sites originally qualified for
participation, three sites, one each in Malawi, South Africa
and Panama, did not recruit any participants. The study
was therefore conducted at ten sites: three in Panama, two
in the Dominican Republic, four in South Africa, and one
in Mozambique (Table 1). The study sites were urban,
except the semirural site in Mozambique.
The study was conducted in accordance with the
principles of Good Clinical Practice and the Declaration
of Helsinki. The study protocol and related documents
were approved by the institutional review boards or
ethics committees in each study country: Comite de
Docencia e Investigación, Hospital Santo Tomás, Panama;
Consejo Nacional de Bioetica en Salud, the Dominican
Republic; University of the Witwatersrand Human Research
Ethics Committee (Medical), South Africa; Health Research
Ethics Committee Research Development and Support
Division, Stellenbosh University, South Africa; and National
Bioethics Health Committee, Mozambique. Written in-
formed consent was obtained from all women, or their
parent/legal representative if minors, prior to enrolment in
the study. Informed assent was also obtained from women
who were classified as minors. The study was registered at
www.clinicaltrials.gov (NCT01734434).
Women who sought antenatal care at the study site
were eligible for participation if they were at ≥24 weeks
(Panama, the Dominican Republic, and site SA_1 in
South Africa) or 28–34 weeks (sites SA_2, SA_3, and
SA_4 in South Africa and the site from Mozambique)
of gestation at enrolment, and if they provided written
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informed consent. Following a protocol amendment, the
gestational age eligibility window was modified to be
consistent with recommendations from the GBS scientific
committee specifying that the investigational GBS vaccine
should be administered in pregnancy between 28 and
34 weeks of gestation. The new criterion for gestational
age was only implemented at three sites from South Africa
and the site in Mozambique (SA_2, SA_3, SA_4, and
MO_1) because the others had already completed
enrolment or were nearing completion at the time of
the protocol amendment.
Data were collected from women at each of the three
study visits (enrolment, delivery, and infant follow-up
visit) by means of questionnaires (Additional file 1). The
follow-up visit occurred when the infants reached 90 days
of age, which is the upper age limit used to define late-
onset GBS infection [12]. The questions were intended
to identify the barriers that may hinder access to health-
care or participation in a future clinical trial for pregnant
women in each of the settings. Questions asked at all
three visits were: duration, cost and type of transportation
to the study site, access to a telephone, and availability of
care for other children. Specific questions at the enrolment
visit (prenatal) were gestational age and its method of
estimation, estimated delivery date, and details of the
clinic for the woman’s well-child visit (immunisation).
At the delivery visit, the time and place of delivery,
labour onset, pregnancy outcome, health status of infant,
and day of discharge were recorded. Women not delivering
at the study site were asked to provide this information
telephonically or by completing the non-study site delivery
questionnaire. If needed, a home visit was undertaken as
per local practice. Additional time points for data collec-
tion were the well-child visit (within 21 days after the
estimated delivery date) or the 90-day follow-up visit. At
the infant follow-up visit (90 days after delivery), the
following information was recorded: the health status of
the infant, the well-child visit attendance, and whether the
infant was sick during the first 90 days of life (in which
case further information was recorded on whether medical
care was sought or not, where medical care was sought, or
the reasons for not seeking medical care). Education about
signs and symptoms of potential sepsis in infants was
provided to nearly all women (97.3%) at enrolment and
at delivery. Women were counselled to seek urgent
medical care if their infant developed any symptom of
sepsis. Potential GBS infections could be detected if
enrolled women identified these specific sepsis symptoms
Table 1 Demographics and baseline characteristics of women included in the full analysis set
Panama Dominican Republic South Africa Mozambique
PA_1 PA_2 PA_3 DR_1 DR_2 SA_1 SA_2 SA_3 SA_4 MO_1
N = 263 N = 63 N = 174 N = 276 N = 224 N = 500 N = 499 N = 500 N = 490 N = 251
Age (years)
Mean ± SD 24.3 ± 5.2 28.8 ± 6.0 25.0 ± 5.6 24.1 ± 5.1 25.0 ± 5.4 29.0 ± 6.4 25.8 ± 5.9 27.4 ± 5.9 26.0 ± 5.4 25.0 ± 6.3
< 18, n (%) 0 (0) 0 (0) 1 (0.6) 1 (0.4) 2 (0.9) 1 (0.2) 0 (0) 1 (0.2) 0 (0) 0 (0)
18–22, n (%) 113 (43.0) 10 (15.9) 71 (40.8) 132 (47.8) 92 (41.1) 92 (18.4) 182 (36.5) 125 (25.0) 150 (30.6) 111 (44.2)
23–27, n (%) 94 (35.7) 20 (31.7) 50 (28.7) 74 (26.8) 67 (29.9) 134 (26.8) 147 (29.5) 147 (29.4) 164 (33.5) 55 (21.9)
28–32, n (%) 32 (12.2) 13 (20.6) 32 (18.4) 43 (15.6) 40 (17.9) 124 (24.8) 93 (18.6) 126 (25.2) 112 (22.9) 47 (18.7)
33–37, n (%) 19 (7.2) 16 (25.4) 15 (8.6) 25 (9.1) 15 (6.7) 97 (19.4) 50 (10.0) 66 (13.2) 47 (9.6) 28 (11.2)
≥ 38, n (%) 5 (1.9) 4 (6.3) 5 (2.9) 1 (0.4) 8 (3.6) 52 (10.4) 27 (5.4) 35 (7.0) 17 (3.5) 10 (4.0)
Gestational age (weeks)
Mean ± SD 28.7 ± 3.7 32.7 ± 4.0 29.6 ± 4.4 33.5 ± 4.8 31.1 ± 4.4 32.7 ± 4.6 30.9 ± 2.0 30.7 ± 1.9 30.8 ± 1.8 30.5 ± 2.3
Gestational age calculation method
Fundal height, n (%) 0 (0) 0 (0) 1 (0.6) 12 (4.3) 1 (0.4) 90 (18.0) 100 (20.0) 263 (52.6) 140 (28.6) 249 (99.2)
Last menstrual period, n (%) 201 (76.4) 36 (57.1) 113 (64.9) 107 (38.8) 139 (62.1) 220 (44.0) 346 (69.3) 181 (36.2) 32 (6.5) 2 (0.8)
Ultrasound, n (%) 62 (23.6) 27 (42.9) 56 (32.2) 156 (56.5) 84 (37.5) 190 (38.0) 53 (10.6) 56 (11.2) 318 (64.9) 0 (0)
Other: Last menstrual period +
ultrasound, n (%)
0 (0) 0 (0) 4 (2.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Women having other children under care
n (%) 151 (57.4) 42 (66.7) 92 (52.9) 183 (66.3) 132 (58.9) 304 (60.8) 286 (57.3) 278 (55.6) 217 (44.3) 182 (72.5)
Women caring for other children with alternative childcare provider available
n (%) 147 (97.4) 37 (88.1) 79 (85.9) 162 (88.5) 124 (93.9) 304 (100) 284 (99.3) 277 (99.6) 215 (99.1) 179 (98.4)
N number of women per group, n (%) number (percentage) of women in each category, SD standard deviation
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in their child. Investigators recorded all study data on
electronic case report forms stored in a secure electronic
data capture system for validation.
The study sample size was driven by the enrolment
capacity of the sites. Summary statistics were calculated
for all recorded questionnaire data, and were presented
as frequencies and percentages. Means and standard
deviations were presented for continuous variables (e.g.
age, gestational age). Analyses were performed on overall
data, by region (Latin America or Africa), by country,
and by study site. Statistical testing was used only for
descriptive purposes, and no multiplicity adjustments
were performed.
Stepwise logistic regressions were performed on all
enrolled women and on those who provided data
after enrolment. Formula and details on odds ratios
(ORs) calculation are given in Supplementary Methods
(Additional file 2).
To evaluate factors that might influence whether pregnant
women would return to study site for delivery, pregnant
women were categorised into two groups: those who
returned to a study site to deliver and those who did not.
Pregnant women whose delivery status was unknown were
grouped with those who delivered at a non-study site. To
explore the seeking of medical attention, only women with a
sick newborn or infant were included for the first occur-
rence of illness. The predictor variables included in the
logistic regressions were: country of study site; age of preg-
nant woman; gestational age of pregnancy at enrolment;
mode, duration, and cost of transportation to the study site;
and alternative childcare (no children, children but with no
alternative childcare, children with alternative childcare).
The stepwise method was used with p-values to enter
factors set at 0.05 and p-values to remove factors set at
0.06. All 95% confidence intervals (CIs) were calculated
using the Clopper-Pearson method. All statistical analyses
were performed using Statistical Analysis System version
9.1 or a later version.
Results
Study participants
In total, 3614 women were approached for enrolment.
Of these, 300 (8.3%) women did not give consent, 67
(1.9%) were not eligible for enrolment, and 4 (0.1%) were
not enrolled for other reasons (Fig. 1). Reasons for not
participating in the study varied by site; overall, gestational
age outside eligibility window was the most common
reason. Other reasons included language difficulties,
relocation or living outside the study area, family reasons,
and lack of interest in participating. Of the 3243 enrolled
women, 3069 (94.6%) completed the study. Reasons for
premature withdrawal were loss to follow-up (n = 90), no
live birth (n = 41), infant death (n = 26), withdrew consent
(n = 13), signed wrong version of consent form (n = 3),
and other (n = 1). Of note, the proportion of women who
withdrew because they had no live birth was higher in
Africa (38 [1.7%; range across sites: 1.0–2.4%]) than in
Latin America (3 [0.3%; range across sites: 0.0–0.6%]),
and among the 26 women prematurely withdrawn from
the study for infant death, 4 (0.4%; range across sites:
0.0–0.7%) were in Latin America and 22 (1.0%; range
across sites: 0.2–2.0%) in Africa.
The mean age and gestational age of enrolled women
were similar across sites (Table 1). The method to
determine gestational age varied by site and/or country.
Fundal height was predominant in Mozambique (99.2%
of women) and at one site in South Africa (site SA_3:
52.6%), compared with last menstrual period (LMP) or
ultrasound at the other sites. An alternative childcare
provider was available at enrolment for 96.8% (range
across sites: 85.9–100%) of women caring for other
children.
Most women were contactable by phone at all sites for
each study visit (range across sites: 75.7–100%). Of those
contactable, 99.4–100% of women in Mozambique were
contactable by personal mobile phone for the three
visits. Personal mobile phone use was also high in
South Africa (range across sites: 96.9–99.8%), but
slightly lower in the Dominican Republic and Panama
(75.8–84.0% and 85.2–96.6%, respectively). No women
in Mozambique were contactable by home phone. Home
phone access was also low in South Africa (0.2–5.2%), but
was higher in the Dominican Republic (18.2–27.8%) and
Panama (29.3–44.4%).
Factors influencing delivery at study site
Among the 3229 enrolled women with delivery informa-
tion, 2053 (63.6%) delivered at the study site, and 1115
(34.5%) delivered at a non-study healthcare facility (Table 2).
There were large differences in percentages of women
Fig. 1 Participant flow diagram
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returning to the study site for delivery, ranging from 25.3–
91.5% across sites. Reasons for a non-study site delivery
were multiple (categorised as “other”) for most women
(79.9%; range across sites: 5.0–95.3%), but the most com-
mon reason given was “labour too fast” (10.0%; range
across sites: 2.5–70.0%) (Table 2).
Both mean age and gestational age were significant
factors influencing whether a woman delivered at the
study site, with older women and women at later gesta-
tional age at enrolment being more likely to deliver at
the study site. With every year increase in the woman’s
age and with every week increase in the gestational age,
the participant was more likely to deliver at the study
site (ORs = 1.02 [95% CI: 1.01, 1.04] and 1.01 [95% CI:
1.01, 1.01], respectively) (Table 3).
Mode of transportation at enrolment or delivery was
similar (data shown for delivery) for all sites within each
country, but varied between countries (Table 4). At the
delivery visit, the most common modes of transportation
in Panama and South Africa were minibus/taxi (43.2%
[range across sites: 31.2–62.1%] and 34.3% [19.0–44.8%],
respectively) and private car (35.6% [26.4–41.1%] and
38.5% [34.2–44.9%], respectively), while public transport
(40.4% [32.1–47.1%]) and minibus/taxi (35.6% [22.5–
51.8%]) were most common in the Dominican Republic
and walking (53.4%) in Mozambique. When compared
to other modes of transportation and holding all other
variables constant in the model, women who used mini-
bus/taxi (OR = 1.26 [95% CI: 1.05, 1.50]) at enrolment
and those who used public transportation (OR = 1.39
[95% CI: 1.07, 1.80]) or walking (OR = 2.56 [95% CI:
1.62, 4.04]) at delivery were more likely to deliver at the
study site, while those reaching the study site by ambu-
lance for delivery (OR = 0.23 [95% CI: 0.18, 0.30]) were
less likely to deliver there (Table 3).
Within a country, travel times to the study site were
similar (Table 4). In Mozambique, most women travelled
30–59 min (67.8%) to reach the study site for delivery.
The majority in the three other countries travelled less
than 45 min (66.4% in the Dominican Republic, 66.0% in
Panama, and 85.7% in South Africa). A short duration of
transportation at delivery was positively associated with
women returning to the study site for delivery. When
comparing women with 15–29 min of transportation to
reach the study site for delivery, those with less than
15 min were more likely (OR = 1.52 [95% CI: 1.15, 2.02])
and those with 30–44 min less likely (OR = 0.50 [95%
CI: 0.41, 0.61]) to deliver at the study site (Table 3).
The mean direct cost of transportation at delivery was
similar at the sites in Panama, the Dominican Republic, and
South Africa ($3.6–$5.9), but much lower in Mozambique
($0.3). With every unit increase in cost of transportation (in
Table 2 Study site and non-study site deliveries for women included in full analysis set with available delivery information
Panama Dominican Republic South Africa Mozambique
PA_1 PA_2 PA_3 DR_1 DR_2 SA_1 SA_2 SA_3 SA_4 MO_1
N = 263 N = 63 N = 174 N = 272 N = 224 N = 497 N = 499 N = 497 N = 489 N = 251
Delivery location
Study site, n (%) 203 (77.2) 43 (68.3) 126 (72.4) 249 (91.5) 91 (40.6) 422 (84.9) 126 (25.3) 414 (83.3) 161 (32.9) 218 (86.9)
Non-study healthcare facility,
n (%)
57 (21.7) 18 (28.6) 48 (27.6) 21 (7.7) 132 (58.9) 68 (13.7) 357 (71.5) 79 (15.9) 315 (64.4) 20 (8.0)
Home, n (%) 0 (0) 2 (3.2) 0 (0) 0 (0) 0 (0) 3 (0.6) 7 (1.4) 2 (0.4) 3 (0.6) 7 (2.8)
Other, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (0.4) 5 (1.0) 1 (0.2) 2 (0.4) 1 (0.4)
Unknown, n (%) 3 (1.1) 0 (0) 0 (0) 2 (0.7) 1 (0.5) 2 (0.4) 4 (0.8) 1 (0.2) 8 (1.6) 5 (2.0)
Reason for non-study site delivery
Labour too fast, n (%) 28 (49.1) 14 (70.0) 8 (16.7) 7 (33.3) 5 (3.8) 15 (20.6) 12 (3.3) 8 (9.6) 8 (2.5) 10 (35.7)
Did not want to deliver at site,
n (%)
5 (8.8) 1 (5.0) 7 (14.6) 1 (4.8) 7 (5.3) 10 (13.7) 5 (1.4) 9 (10.8) 1 (0.3) 0 (0)
Family did not allow, n (%) 1 (1.8) 0 (0) 1 (2.1) 0 (0) 0 (0) 5 (6.9) 4 (1.1) 15 (18.1) 8 (2.5) 0 (0)
No direct transportation to site,
n (%)
0 (0) 2 (10.0) 19 (39.6) 0 (0) 0 (0) 0 (0) 1 (0.3) 2 (2.4) 0 (0) 3 (10.7)
No money for transportation,
n (%)
0 (0) 2 (10.0) 10 (20.8) 0 (0) 0 (0) 2 (2.7) 1 (0.3) 0 (0) 0 (0) 0 (0)
No childcare available for other
children, n (%)
0 (0) 0 (0) 0 (0) 0 (0) 1 (0.8) 0 (0) 1 (0.3) 0 (0) 0 (0) 1 (3.6)
Othera, n (%) 25 (43.9) 1 (5.0) 3 (6.3) 14 (66.7) 120 (90.9) 41 (56.2) 349 (94.6) 48 (57.8) 305 (95.3) 14 (50.0)
N number of women per group, n (%) number (percentage) of women in each category
aOther: includes another hospital or healthcare centre was closer, women had a healthcare insurance coverage or a relative working at another healthcare facility,
no free beds at study site, pregnancy complications/emergencies, away from area at time of labour
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United States dollar [USD]) at enrolment, the women were
1.09 (95% CI: 1.02, 1.16) times more likely to deliver at the
study site (Table 3).
Outcome at the 90-day infant follow-up visit
In total, 97.8% of women with live-born infants (3077/
3145) provided 90-day infant follow-up information, but
only 2121 of them (68.9%) returned to the study site for
this visit. The overall percentage of women returning
to the study site was similar in Mozambique, Panama,
and South Africa (62.2–68.2%), but much higher in the
Dominican Republic (98.0%), with significant inter-site
differences within countries (Fig. 2). At the 90-day infant
follow-up visit, information was available for 3106 infants,
Table 3 Predictor variables included in the logistic regression model for study site delivery and follow-up visit
Parameter estimate Odds ratio (95% CI) p-value
Factors influencing delivery at the study site (full analysis set)
Country of study site
Dominican Republic vs South Africa −0.61 1.15 (0.87, 1.52) <0.0001
Mozambique vs South Africa 1.19 6.96 (4.14, 11.69) <0.0001
Panama vs South Africa 0.17 2.50 (1.93, 3.23) 0.1391
Age of the pregnant women 0.02 1.02 (1.01, 1.04) 0.0008
Gestational age 0.01 1.01 (1.01, 1.01) <0.0001
Mode of transportation
Minibus/Taxi - Visit 1 (Yes vs No) 0.11 1.26 (1.05, 1.50) 0.0123
Public transportation - Visit 2 (Yes vs No) 0.16 1.39 (1.07, 1.80) 0.0124
Walk - Visit 2 (Yes vs No) 0.47 2.56 (1.62, 4.04) <0.0001
Ambulance - Visit 2 (Yes vs No) −0.73 0.23 (0.18, 0.30) <0.0001
Duration of transportation to study site (Visit 1)
< 15 min vs 15–29 min −0.35 0.73 (0.58, 0.92) 0.0131
30–44 min vs 15–29 min −0.06 0.98 (0.79, 1.21) 0.6716
45–59 min vs 15–29 min 0.33 1.43 (1.03, 1.99) 0.0477
60–89 min vs 15–29 min 0.19 1.26 (0.88, 1.80) 0.2515
90–120 min vs 15–29 min −0.11 0.93 (0.50, 1.73) 0.6957
> 120 min vs 15–29 min 0.03 1.06 (0.31, 3.66) 0.9592
Duration of transportation to study site (Visit 2)
< 15 min vs 15–29 min 0.70 1.52 (1.15, 2.02) <0.0001
30–44 min vs 15–29 min −0.42 0.50 (0.41, 0.61) 0.0007
45–59 min vs 15–29 min −0.09 0.69 (0.52, 0.93) 0.5444
60–89 min vs 15–29 min 0.04 0.79 (0.56, 1.12) 0.8159
90–120 min vs 15–29 min 0.23 0.96 (0.50, 1.85) 0.4259
> 120 min vs 15–29 min −0.74 0.36 (0.11, 1.18) 0.1507
Cost of transportation to study site (Visit 1) 0.08 1.09 (1.02, 1.16) 0.0133
Factors influencing return to the study site for follow-up visit (full analysis set with live-born infants)
Country of study
Dominican Republic vs South Africa 2.40 19.20 (10.16, 36.27) <0.0001
Mozambique vs South Africa −1.32 0.46 (0.32, 0.67) <0.0001
Panama vs South Africa −0.52 1.03 (0.82, 1.29) <0.0001
Mode of transportation to study site
Walk - Visit 2 (Yes vs No) 0.31 1.85 (1.21, 2.81) 0.0042
Cost of transportation to study site at Visit 2 −0.01 0.99 (0.97, 1.00) 0.0257
Alternative Childcare at Visit 1
Alternative care available vs No other children 0.21 1.35 (1.14, 1.60) 0.1115
CI confidence intervals, Visit 1 enrolment, Visit 2 delivery
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of whom 3089 (99.5%) attended at least one well-child
visit at the study site or another healthcare facility.
Women who walked to the site for delivery were sig-
nificantly more likely to return to the study site for the
infant follow-up visit (OR = 1.85 [95% CI: 1.21, 2.81]).
Cost of transportation calculated at delivery was also a
significant factor influencing whether women returned
to the study site for the infant follow-up visit. With
every unit increase in cost of transportation (in USD) at
delivery, the women were 0.99 (95% CI: 0.97, 1.00) times
less likely to return to the study site for their follow-up
visit (Table 3).
Alternative childcare availability was very high (96.8%;
range across sites: 85.9–100%) (Table 1), and women
with alternative childcare provider availability at enrol-
ment, representing women with children, were more
likely to return to the study site for follow-up than
those without other children (OR = 1.35 [95% CI: 1.14,
1.60) (Table 3).
Sick child reporting and medical care
Of the 3199 live born infants, 218 (6.8%; range across
sites: 2.0–19.3%) newborns were reported sick before
discharge. Overall, the highest percentage of newborns
reported sick was in Panama (16.3%) and the lowest in
Mozambique (2.1%), but this percentage varied across
sites within each country. At the 90-day infant follow-up
visit, 666/3106 (21.4%; range across sites: 3.7–68.8%)
infants were reported sick during the first 90 days of life;
this percentage was lower in Africa (11.3%) compared
to Latin America (43.3%). Of these 666 infants, 94.3%
(range across sites: 82.2–100%) were taken to a health-
care facility, and 41.9% (range across sites: 4.9–77.3%)
were taken to the study site (Table 5). The most common
Table 4 Transportation to site/healthcare facilities at delivery for women included in the full analysis set
Panama Dominican Republic South Africa Mozambique
PA_1 PA_2 PA_3 DR_1 DR_2 SA_1 SA_2 SA_3 SA_4 MO_1
N = 263 N = 63 N = 174 N = 276 N = 224 N = 500 N = 499 N = 500 N = 490 N = 251
Mode of transportationa
Ambulance, n (%) 13 (4.9) 10 (15.9) 3 (1.7) 0 (0) 0 (0) 69 (13.8) 35 (7.0) 32 (6.4) 174 (35.5) 11 (4.4)
Minibus/taxi, n (%) 82 (31.2) 26 (41.3) 108 (62.1) 62 (22.5) 116 (51.8) 224 (44.8) 173 (34.7) 192 (38.4) 93 (19.0) 5 (2.0)
Private car, n (%) 108 (41.1) 24 (38.1) 46 (26.4) 64 (23.2) 26 (11.6) 189 (37.8) 224 (44.9) 171 (34.2) 182 (37.1) 44 (17.5)
Public transportation,
n (%)
60 (22.8) 4 (6.3) 19 (10.9) 130 (47.1) 72 (32.1) 1 (0.2) 44 (8.8) 75 (15.0) 5 (1.0) 41 (16.3)
Walk, n (%) 8 (3.0) 0 (0) 0 (0) 41 (14.9) 12 (5.4) 11 (2.2) 16 (3.2) 10 (2.0) 16 (3.3) 134 (53.4)
Other, n (%) 0 (0) 0 (0) 0 (0) 24 (8.7) 5 (2.2) 0 (0) 1 (0.2) 7 (1.4) 0 (0) 4 (1.6)
Duration of travel
< 15 min, n (%) 13 (4.9) 5 (7.9) 39 (22.4) 17 (6.2) 26 (11.6) 76 (15.2) 41 (8.2) 73 (14.6) 46 (9.4) 7 (2.8)
15–29 min, n (%) 85 (32.3) 23 (36.5) 54 (31.0) 59 (21.4) 83 (37.1) 209 (41.8) 219 (43.9) 295 (59.0) 199 (40.6) 20 (8.0)
30–44 min, n (%) 61 (23.2) 11 (17.5) 39 (22.4) 71 (25.7) 76 (33.9) 133 (26.6) 170 (34.1) 80 (16.0) 163 (33.3) 85 (33.9)
45–59 min, n (%) 23 (8.7) 7 (11.1) 16 (9.2) 49 (17.8) 19 (8.5) 65 (13.0) 35 (7.0) 27 (5.4) 38 (7.8) 85 (33.9)
60–89 min, n (%) 61 (23.2) 14 (22.2) 16 (9.2) 56 (20.3) 14 (6.3) 8 (1.6) 20 (4.0) 8 (1.6) 17 (3.5) 30 (12.0)
90–120 min, n (%) 11 (4.2) 1 (1.6) 6 (3.4) 17 (6.2) 4 (1.8) 3 (0.6) 7 (1.4) 3 (0.6) 2 (0.4) 9 (3.6)
> 120 min, n (%) 4 (1.5) 0 (0) 3 (1.7) 1 (0.4) 0 (0) 0 (0) 0 (0) 1 (0.2) 2 (0.4) 3 (1.2)
Cost ($)
mean ± SD 5.4 ± 6.5 5.9 ± 6.0 5.2 ± 4.5 3.6 ± 3.8 4.8 ± 3.1 5.1 ± 6.7 3.8 ± 6.6 5.0 ± 6.8 4.9 ± 7.0 0.3 ± 1.0
N number of women per group, n (%) number (percentage) of women in each category, SD standard deviation
aThe women participating in the study were allowed to indicate more than 1 way of transportation, the most frequent combination was “public transportation
& walk”
Fig. 2 Percentage of women returning to the study site for infant
follow-up visit, 90 days post-delivery
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reason for the sick infant not being taken to a healthcare
facility was that the infant did not appear seriously ill (31/
38 infants, 81.6%). Other factors were lack of money and
“other” (e.g. infant already hospitalised, infant died before
reaching healthcare).
Discussion
This study identified factors influencing whether pregnant
women would enrol in clinical trials, and would return to
study sites for delivery, infant follow-up visits, or to seek
medical assistance for their sick infant. By identifying
restrictions to maternal/infant healthcare access in poten-
tial clinical sites, this study provided a potential platform
for improving compliance and retention for future phase
3 clinical efficacy studies of investigational GBS vaccines.
Apart from greater efficiency in clinical trials, there is
evidence that ante- and post-partum visits improve mater-
nal and infant health, and increase perinatal infant survival
rates by offering opportunities for education and medical
interventions. A greater understanding of predictors of
pregnant women access to healthcare services may
therefore also have programmatic implications for the
improvement of healthcare utilisation.
Out of all pregnant women who were approached, 10%
were not eligible for the study and could not participate.
The reasons for not participating were estimated with the
most common being lower than required gestational age.
Proportions of ineligible women and reasons for ineligibility
will be useful in the operational planning of clinical trials
enrolling pregnant women, e.g. women with too low
gestational age at screening could potentially partici-
pate if they return later during pregnancy.
Women at later gestational age at enrolment were more
likely to deliver at the study site. In clinical trials, the
gestational age is estimated to identify the appropriate
time for maternal vaccination to ensure optimum placen-
tal antibody transfer to the infant [13]. Here, methods of
estimating gestational age varied among sites, the most
common being ultrasound or LMP in Latin America and
South Africa, and fundal height in Mozambique. Ultra-
sound is considered the most accurate method, but is less
available in resource-limited settings [13–15]. The LMP
method can be universally applied, but relies on self-
assessment and reporting, and is potentially unreliable
[14]. The fundal height method is routinely used in many
resource-limited countries [16].
Older women were also more likely to return to study
sites for delivery. This observation is in line with previous
studies suggesting that women in their 30s attended ante-
natal healthcare more frequently than younger or older
women, but contrasts with other studies suggesting that age
had no effect on antenatal healthcare utilisation [17].
Another finding was that women with other children were
more likely to return to study site for follow-up visits. A
potential explanation for this unexpected finding could
be that multiparous women often return to the site of
their previous delivery for antenatal visits and are there-
fore more likely to return to the same site for delivery and
follow-up visits.
Additionally, we identified factors that may hinder
access to healthcare facilities for pregnant women and
Table 5 Medical assistance for infants reported sick within 90 days post-delivery
Panama Dominican Republic South Africa Mozambique
PA_1 PA_2 PA_3 DR_1 DR_2 SA_1 SA_2 SA_3 SA_4 MO_1
N = 254 N = 61 N = 176 N = 269 N = 221 N = 487 N = 480 N = 485 N = 441 N = 232
Infant reported sick in first 90 days
n (%) 127 (50.0) 32 (52.5) 121 (68.8) 104 (38.7) 41 (18.6) 18 (3.7) 41 (8.5) 43 (8.9) 73 (16.6) 66 (28.5)
Sick infant taken to
Study site, n (%) 58 (45.7) 12 (37.5) 77 (63.6) 27 (26.0) 27 (65.9) 7 (38.9) 2 (4.9) 13 (30.2) 5 (6.9) 51 (77.3)
Infant’s hospital/immunisation clinic,
n (%)
2 (1.6) 6 (18.8) 7 (5.8) 10 (9.6) 3 (7.3) 10 (55.6) 13 (31.7) 10 (23.3) 21 (28.8) 13 (19.7)
Other, n (%) 65 (51.2) 14 (43.8) 34 (28.1) 61 (58.7) 8 (19.5) 1 (5.6) 22 (53.7) 15 (34.9) 34 (46.6) 0 (0)
Not taken to healthcare facility, n (%) 2 (1.6) 0 (0) 3 (2.5) 6 (5.8) 3 (7.3) 0 (0) 4 (9.8) 5 (11.6) 13 (17.8) 2 (3.0)
Reasons for not taking sick infant to healthcare facility
Newborn did not appear seriously ill,
n (%)
0 (0) 0 (0) 3 (100) 4 (66.7) 3 (100) 0 (0) 3 (75.0) 4 (80.0) 13 (100) 1 (50.0)
Lack of money, n (%) 1 (50.0) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Lack of transportation, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
No alternative childcare available,
n (%)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Other, n (%) 1 (50.0) 0 (0) 0 (0) 1 (16.7) 0 (0) 0 (0) 1 (25.0) 1 (20.0) 0 (0) 1 (50.0)
N infants with information available at 90 days follow-up, n (%) number (percentage) of subjects in each category
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their infants. Mode, duration, and cost of transportation had
a significant influence on whether women would return to
study site for delivery and follow-up visits. Transportation
was previously identified as a barrier for access to obstetric
care in low- and middle-income countries, with increasing
cost, distance, and travel time reducing the likelihood of
returning [17–20]. Surprisingly, we found that increased
transportation costs at enrolment, which were lower than
transportation costs at delivery, were associated with
increased likelihood of women returning to study sites
for delivery. This observation suggests that women who
can afford to pay for transportation to antenatal visits
are more likely to return to the same site for delivery.
Another potential explanation could be that women living
further from the study site may stay nearby when their
due date was coming closer, which would then decrease
the transportation costs at delivery. In contrast, lower
transportation costs at delivery were associated with an
increased likelihood of women returning to the study site
for follow-up visits. Our results suggest that transporta-
tion cost is a barrier for routine follow-up visits, but not
for hospital delivery, which is an important finding to
consider when preparing clinical trials on maternal im-
munisation. In Africa, this finding should be interpreted
with caution considering the differences in minimum
salary in the respective countries [21].
Over 90% of women sought medical care at the study
site or another healthcare facility for their sick infant,
suggesting that the probability to detect potential GBS
infections was high. However, more widespread efforts
are needed to collect detailed follow-up information
since only two thirds of live born infants were brought
to the study site for the 90-day follow-up visits. Each site
from a clinical study should establish surveillance in
surrounding facilities where sick infants may be seen.
The study had a number of limitations. Although edu-
cation about signs and symptoms of sepsis was provided
to nearly all women, the study failed to clearly define
what “sick” or “illness” meant, allowing thresholds for
considering a child as ill that could differ by country. In
addition, the incidence and causes of disease in infants
were not collected as the majority of sick children were
not assessed at the study site. When choosing sites for
potential phase 3 trials on investigational maternal GBS
vaccines, it is important to understand the neonatal invasive
GBS disease incidence in the area; however, these estimates
are lacking for many low- and middle-income countries
[22]. The low proportion of women younger than 18 years
of age (0.2%) was another potential limitation. Indeed, 16%
of pregnant women in sub-Saharan Africa are under
19 years [23]; these young women are often at higher risk
for GBS due to a lack of sexual health education [24] and a
lower level of natural immunity against colonisation. Young
pregnant women are an important group to study because
they are often underrepresented in clinical trials due to legal
or logistical reasons. This study was also limited by the fact
that only healthcare sites large enough to conduct phase 3
clinical trials were used. These were in large urban areas,
except the semirural site in Mozambique. Therefore, factors
influencing whether women would return to healthcare
facilities may vary for rural areas and smaller healthcare
sites. The absence of data on the following variables was a
further limitation of this study: the mode of delivery, the
occurrence of complications during delivery, and the quality
of the antenatal and birthing experience, which may all
impact the likelihood of returning for a follow-up visit.
Finally, failure to collect information on the impact of other
important factors, such as education, parity, and income,
was another limitation [25, 26].
Conclusions
In this prospective, multi-centre, observational study,
older pregnant women and those at later gestational age
at enrolment were more likely to deliver at the study site.
Women with other children were more likely to return to
study site for follow-up visits. While heterogeneities were
observed at site level, shorter travel time at delivery and
increased transportation costs at enrolment were associ-
ated with increased likelihood of women returning to study
site for delivery. Lower transportation costs at delivery
were associated with increased likelihood of women
returning to study site for follow-up visits. Although
high retention was observed from enrolment through
90 days after delivery, post-partum surveillance should
be broadened beyond the study sites and an additional
follow-up visit should be planned within the first
month of life, the most vulnerable time for a child’s
survival. The factors influencing maternal/infant access
to healthcare facilities and the issues identified in this
study should be taken into consideration in planning
future clinical studies on maternal immunisation in
low- and middle-income countries.
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